Southlake Clinic
Endocrinology and Internal Medicine Practice

RAINIER CLINICAL RESEARCH CENTER
Director and Principal Investigator

OFFICE ADDRESS
723 SW 10th Street, Suite 100
Renton, Washington 98057
(425) 251-1720 | (425) 251-1723 fax | Email Ronald Brazg

Personal
Date of Birth: October 11, 1957

Academic Position
1992- Clinical Assistant Professor of Medicine
Division of Metabolism and Endocrinology
University of Washington, Seattle, WASHINGTON.

Postgraduate Training
AACE Certification in Thyroid Ultrasound
1990-1992 Senior Fellow in Endocrinology and Metabolism
University of Washington, Seattle, Washington
1989-1990 Chief Resident and Attending Physician in Internal Medicine
Sinai Hospital, Detroit, Michigan
1987-1989 Senior Resident in Internal Medicine
Sinai Hospital, Detroit, Michigan
1986-1987 Research Physician--Diabetes Program
Wayne State University, Detroit, Michigan
1984-1986 Resident in Internal Medicine
Baragwanath Hospital and University of the Witwatersrand, Johannesburg, South Africa
1982-1983 SADF--Mandatory National Service
Rank: Full Lieutenant (medical officer), Family Practice, Internal Medicine and Emergency Medicine.
1980-1981 Internship (General Surgery and Internal Medicine)
Hillbrow Hospital and University of the Witwatersrand, Johannesburg, South Africa

Education
1980 University of Witwatersrand, Medical School, Johannesburg, South Africa, M.B.B.Ch.
1974 Matriculated from Parktown Boys' High School
with honors in Math, Physical Science, Latin, and Accountancy

Hospital Positions
1992- Clinical Assistant Professor
Division of Metabolism & Endocrinology, University of Washington,
Seattle, Washington
1992- Medical Staff
Valley Medical Center, Renton, Washington (VMC)
1996-1997 Vice Chairman, Department of Medicine VMC
Medical Director – HMR Weight Management Program VMC
Medical Director – Diabetes Education Program VMC

Board Certifications
1993 Endocrinology, Diabetes & Metabolism
1990 American Board of Internal Medicine

Licensure to Practice
1990- State of Washington
1986-1990 State of Michigan

Professional Organization Membership
1993- American Diabetes Association
1992- King County Medical Society
1992- Washington State Medical Association
1993-1997 American Heart Association - Past President, Springbrook Division, WA
1997-1999 Valley Physicians Organization – Past Chairman, Contract Committee
Member, Value Analysis Committee
2002 American Association of Clinical Endocrinologists Fellow (2003)

BIBLIOGRAPHY
1. Chait A, Brazg RL, and Krauss RM: Increased oxidative susceptibility of LDL subfractions in subjects with the atherogenic lipoprotein phenotype. Arteriosclerosis and Thrombosis 11(5):1425A, 1991.
2. Brazg RL, Duell PB, Gilmore M, Bierman EL, and Chait A: Effects of dietary antioxidants on LDL oxidation in non-insulin-dependent diabetes. Clin Res 40(1):103A, 1992.
3. Zambon S, Brazg RL, Aviram M, Oram JF, and Bierman EL: The effect of probucol on HDL-mediated sterol translocation and efflux from cells. Atherosclerosis 94(1):51-60, 1992.
4. James J. Maciejko, M.S., Ph.D., Ronald Brazg, M.D., Aajay Shah, M.D., et.al.: Psyllium fiber reduces the gastrointestinal symptomatology associated with cholestyramine in the treatment of primary hypercholesterolemia. Arch Fam Med/Vol 1. Sept. 1992.
5. Chait A, Brazg RL, Tribble DL, and Krauss RM: Susceptibility of small, dense low density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med - 94 (4) 350-356, 1993.
6. Brazg RL and Bierman EL: Insulin excess counteracts the effects of HDL on intracellular sterol accumulation. Diabetologia, 36:942-947, 1993.
Brazg RL: Is Glycemic control enough to control the dyslipidemia in NIDDM. Clinical Diabetes, 11;117, 1993.
Brazg RL, Decherney S et al; Safety and efficacy of a novel extended release formulation of metformin in patients with Type II Diabetes – A dose-ranging study. Abstr. Diabetes 49; A99, 2000
Insull W Jr, Isaacsohn J, Kwiterovich P, Ra P, Brazg R, Dujovne C, Shan M, Shugrue-Crowley E, Ripa S, Tota R: Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. 
J Int Med Res. 2000 Mar-Apr; 28(2):47-68
J. Isaacsohn, W. Insull, E. Stein, P. Kwiterovich, P. Ma, R. Brazg, C. Dujovne, M. Shan, E. Shurgrue-Crowley, S. Ripa, R. Tota, for the Cerivastatin Study Group.
Clin. Cardiol. Vol 24, (Suppl. IV), IV-1-IV-9, 2001
D.B.Hunninghake, M.D.,M.E. McGovern, M.D., M. Koren, M.D., R. Brazg, M.D., D. Murdock, M.D., S. Weiss, M.D., T. Pearson, M.D., Ph.D.: A Dose-Ranging Study of a New, Once-Daily, Dual-Component Drug Product Containing Niacin Extended-Release and Lovastatin.
Clinical Cardiology Vol. 26, No. 3, March 2003
Feldman B, Brazg R, Schwartz S, Weinstein R: A continuous glucose sensor based on wired enzyme technology-results from a three day trial in patients with Type 1 diabetes.
Diabetes Technol. Ther. 2033: 5(5): 769-779
Ehlers MR, Klaff LJ, D’Alessio DA, Brazg R, Kay HD, Harley RE, Mathisen AL, Schneider R
Recombinant glucagons-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Horm Metab Res. 2003 Oct;35 (10):611-6
K. Fujioka, R.L. Brazg, I. Raz, S. Bruce, S. Joyal, R. Swanink, M.Pans
Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies.
Diabetes, Obesity and Metabolism, 7, 2005, 28-39
Julio Rosenstock, MD, Ronald Brazg, MD, Paula J. Andryuk, BS, Kaifeng Lu, PhD, and Peter Stein, MD, for the Sitagliptin Study 019 Group
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazine therapy in patients with Type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel group study.
Clinical Therapeutics/Volume 28, Number 10, 2006
R. Brazg, L. Xu, C. Dalla Man, C. Cobelli, K. Thomas, P.P. Stein
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, To metformin on 24-hour glycaemic control and b-cell function in patients with type 2 diabetes.
Diabetes, Obesity and Metabolism, 9, 2007, 186-193

EDUCATIONAL
1. Cell membrane receptors and their modulation by membrane phospholipids in normal and disease states. Diabetes and Obesity. Diabetes Program, Wayne State University, Detroit, MI, 1986-1987.
2. High density lipoprotein metabolism in human monocytes. Awarded first prize for best scientific presentation, Sinai Hospital, Detroit, MI, 1989-1990.
3. Honored for Contribution to Medical Education, Sinai Hospital, Detroit, MI, 1989
Excellence in Teaching Award, Valley Medical Center, 1995
Excellence in Teaching Award, Valley Medical Center, 1996
“Best Doctors in America” 2002/2003
“Best Doctors in America” 2003/2004

CLINICAL RESEARCH
1992-present Rainier Clinical Research Center, Inc.
Principal Investigator or Sub-Investigator on over 250 clinical trials
Phase I-IV

Revised 2/16/2007 | Back to Top